E-resources
PDF-
Ramalingam, Suresh S; Vansteenkiste, Johan; Planchard, David; Cho, Byoung Chul; Gray, Jhanelle E; Ohe, Yuichiro; Zhou, Caicun; Reungwetwattana, Thanyanan; Cheng, Ying; Chewaskulyong, Busyamas; Shah, Riyaz; Cobo, Manuel; Lee, Ki Hyeong; Cheema, Parneet; Tiseo, Marcello; John, Thomas; Lin, Meng-Chih; Imamura, Fumio; Kurata, Takayasu; Todd, Alexander; Hodge, Rachel; Saggese, Matilde; Rukazenkov, Yuri; Soria, Jean-Charles
New England journal of medicine/The New England journal of medicine, 01/2020, Volume: 382, Issue: 1Journal Article
Osimertinib was compared with standard EGFR blockers among patients with non–small-cell lung cancer with activating mutations in EGFR . The median overall survival was 38.6 months with osimertinib and 31.8 months with erlotinib or gefitinib. This 20% lower risk of death was noted despite the crossover of patients from standard therapy to osimertinib during subsequent therapy.
